Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25C | P30307 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15719898 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HSD17B10TSHRCA1CA2 | |
| SCHEMBL22805717 | 0.76 | CYP2C9 (0.60) | ALDH1A1HSD17B10CYP1A2TP53CYP2C9 | |
| SCHEMBL3681837 | 0.74 | TSHR (0.68) | ALDH1A1HSD17B10TSHRCYP1A2MAPT | |
| SCHEMBL2907208 | 0.74 | CA12 (0.48) | ALDH1A1HSD17B10TSHRCYP1A2MAPT | |
| SCHEMBL2902318 | 0.73 | CA12 (0.47) | ALDH1A1HSD17B10TSHRCYP1A2MAPT | |
| SCHEMBL4207676 | 0.73 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TSHRCYP1A2MAPT | |
| SCHEMBL18526159 | 0.73 | TSHR (0.66) | ALDH1A1HSD17B10TSHRCYP1A2MAPT | |
| SCHEMBL13975816 | 0.73 | KCNH2 (0.47) | ALDH1A1HSD17B10CYP1A2HPGD | |
| SCHEMBL5125503 | 0.73 | TSHR (0.56) | ALDH1A1HSD17B10TSHRCYP1A2MAPT | |
| SCHEMBL27424975 | 0.72 | TSHR (0.70) | ALDH1A1HSD17B10TSHRCYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709989-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| WO-2012156498-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | TLR3, TLR5, TLR4 | ALDH1A1 4174/4885HSD17B10 4781/4885TSHR 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.